Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 9/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | THRB | P10828 | 1/20 | 0.50 |
| ▸ | FAAH | O00519 | 1/20 | 0.47 |
| ▸ | HPGDS | O60760 | 1/20 | 0.47 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.45 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.44 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.44 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.44 |
| ▸ | TNK2 | Q07912 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18476584 | 0.93 | GPR119 (0.47) | GPR119KDM4EMAPTTHRBFAAH | |
| SCHEMBL34474154 | 0.92 | HPGDS (0.48) | GPR119KDM4EMAPTTHRBFAAH | |
| SCHEMBL18788561 | 0.84 | GPR119 (0.48) | GPR119KDM4EMAPTTHRBFAAH | |
| SCHEMBL18476581 | 0.83 | CHRM4 (0.41) | GPR119KDM4EMAPTTHRBFAAH | |
| SCHEMBL18212354 | 0.82 | F10 (0.45) | — | |
| SCHEMBL16457178 | 0.81 | GPR119 (0.46) | GPR119KDM4EMAPTTHRBFAAH | |
| SCHEMBL17001778 | 0.81 | CHRM4 (0.49) | GPR119HPGDSTNK2 | |
| SCHEMBL18788562 | 0.81 | GPR119 (0.47) | GPR119KDM4EMAPTTHRBFAAH | |
| SCHEMBL3562965 | 0.81 | GPR119 (0.57) | GPR119KDM4EMAPTTHRBHPGDS | |
| SCHEMBL16992086 | 0.80 | F10 (0.47) | TNK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4714446-A2 | PHARMACEUTICAL COMPOUNDS | Nxera Pharma UK Limited (GB) | 2026-03-25 | — | — | EP | disclosed |
| EP-4413985-A2 | PHARMACEUTICAL COMPOUNDS | Nxera Pharma UK Limited (GB) | 2024-08-14 | — | — | EP | disclosed |
| CN-109851610-B | Bicyclic aza compounds as muscarinic M1 and/or M4 receptor agonists | 赫普泰雅治疗有限公司 | 2021-09-21 | — | — | CN | disclosed |
| US-10961225-B2 | Bicyclic AZA compounds as muscarinic M1 receptor and/or M4 receptor | HEPTARES THERAPEUTICS LIMITED (GB) | 2021-03-30 | — | — | US | disclosed |
| US-10961225-B2 | Bicyclic AZA compounds as muscarinic M1 receptor and/or M4 receptor | HEPTARES THERAPEUTICS LIMITED (GB) | 2021-03-30 | — | — | US | disclosed |
| US-20200325118-A1 | BICYCLIC AZA COMPOUNDS AS MUSCARINIC M1 RECEPTOR AND/OR M4 RECEPTOR | NXERA PHARMA UK LIMITED (GB) | 2020-10-15 | — | — | US | disclosed |
| US-20200325118-A1 | BICYCLIC AZA COMPOUNDS AS MUSCARINIC M1 RECEPTOR AND/OR M4 RECEPTOR | NXERA PHARMA UK LIMITED (GB) | 2020-10-15 | — | — | US | disclosed |
| US-10689368-B2 | Bicyclic aza compounds as muscarinic M1 receptor and/or M4 receptor | HEPTARES THERAPEUTICS LIMITED (GB) | 2020-06-23 | — | — | US | disclosed |
| US-10689368-B2 | Bicyclic aza compounds as muscarinic M1 receptor and/or M4 receptor | HEPTARES THERAPEUTICS LIMITED (GB) | 2020-06-23 | — | — | US | disclosed |
| US-20190337925-A1 | BICYCLIC AZA COMPOUNDS AS MUSCARINIC M1 RECEPTOR AND/OR M4 RECEPTOR | NXERA PHARMA UK LIMITED (GB) | 2019-11-07 | — | — | US | disclosed |
| WO-2015118342-A1 | BICYCLIC AZA COMPOUNDS AS MUSCARINIC M1 RECEPTOR AGONISTS. | HEPTARES THERAPEUTICS LIMITED (GB) | 2015-08-13 | — | — | WO | disclosed |
| US-8603975-B2 | Cyclic peptide compounds | ASTELLAS PHARMA INC. (JP) | 2013-12-10 | — | — | US | disclosed |
| EP-2150269-B1 | NEW CYCLIC PEPTIDE COMPOUNDS | ASTELLAS PHARMA INC (JP) | 2012-11-21 | — | — | EP | disclosed |
| EP-2455098-A1 | New cyclic peptide compounds | Astellas Pharma Inc. (JP) | 2012-05-23 | — | — | EP | disclosed |
| US-20110009389-A1 | IMIDAZOLE DERIVATIVE, THEIR PRODUCTION AND USE | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-01-13 | — | — | US | disclosed |
| US-20100120672-A1 | CYCLIC PEPTIDE COMPOUNDS | ASTELLAS PHARMA INC. (JP) | 2010-05-13 | — | — | US | disclosed |
| EP-2150269-A1 | NEW CYCLIC PEPTIDE COMPOUNDS | Astellas Pharma Inc. (JP) | 2010-02-10 | — | — | EP | disclosed |
| WO-2008139986-A1 | NEW CYCLIC PEPTIDE COMPOUNDS | ASTELLAS PHARMA INC., (JP) | 2008-11-20 | — | — | WO | disclosed |
| US-20070004736-A1 | Imidazole derivative, process for producing the same, and use | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-01-04 | — | — | US | disclosed |
| EP-1564213-A1 | IMIDAZOLE DERIVATIVE, PROCESS FOR PRODUCING THE SAME, AND USE | Takeda Pharmaceutical Company Limited (JP) | 2005-08-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200325118-A1 | BICYCLIC AZA COMPOUNDS AS MUSCARINIC M1 RECEPTOR AND/OR M4 RECEPTOR | CHRM1, CHRM2, CHRM4 | GPR119 74/4885KDM4E 1019/4885MAPT 3528/4885 |
| US-20100120672-A1 | CYCLIC PEPTIDE COMPOUNDS | VIP, HAVCR2, ZC3HAV1 | GPR119 1509/4885KDM4E 4413/4885MAPT 4380/4885 |
| US-20070004736-A1 | Imidazole derivative, process for producing the same, and use | HRH4, F2, HRH2 | GPR119 1327/4885KDM4E 1356/4885MAPT 4771/4885 |
| US-20110009389-A1 | IMIDAZOLE DERIVATIVE, THEIR PRODUCTION AND USE | F2, H1-3, CYC1 | GPR119 1118/4885KDM4E 1558/4885MAPT 4800/4885 |
| US-10961225-B2 | Bicyclic AZA compounds as muscarinic M1 receptor and/or M4 receptor | CHRM1, CHRM2, CHRM4 | GPR119 74/4885KDM4E 1019/4885MAPT 3528/4885 |
| US-10689368-B2 | Bicyclic aza compounds as muscarinic M1 receptor and/or M4 receptor | CHRM1, CHRM2, CHRM4 | GPR119 74/4885KDM4E 1019/4885MAPT 3528/4885 |
| US-20190337925-A1 | BICYCLIC AZA COMPOUNDS AS MUSCARINIC M1 RECEPTOR AND/OR M4 RECEPTOR | CHRM1, CHRM2, CHRM4 | GPR119 74/4885KDM4E 1019/4885MAPT 3528/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.